GRAIL (NASDAQ:GRAL) Posts Earnings Results

GRAIL (NASDAQ:GRAL) released its quarterly earnings results on Thursday. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89, Zacks reports. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The business had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million.

Here are the key takeaways from GRAIL’s conference call:

• Top-line NHS‑Galleri results showed a >20% reduction in stage‑4 diagnoses in rounds 2–3, a fourfold higher overall cancer detection rate versus standard of care, increased stage‑1/2 detections, fewer emergency presentations, and no serious safety signals—what GRAIL calls the first randomized population‑scale stage shift for an MCED test.
• Despite those benefits, the trial did not meet its primary endpoint of a statistically significant reduction in combined stage‑3 and stage‑4 cancers; GRAIL plans to extend follow‑up by 6–12 months citing higher‑than‑expected stage‑3 incidence and expects effects may strengthen with more mature data.
• GRAIL completed its PMA submission to the FDA (end of January) using PATHFINDER2 and the NHS prevalent‑round data and anticipates a ~12‑month review, while new federal law creates a Medicare coverage pathway for FDA‑approved MCED tests.
• Commercial momentum continued: >185,000 U.S. Galleri tests sold in 2025 (volume +36%), U.S. revenue +26%, ~17,000 prescribers (+30%), and the company is expanding its field sales/medical teams while reiterating 2026 sales growth guidance of 22–32% and cash burn ≤$300M.
• Financials improved (higher adjusted gross profit and improved adjusted EBITDA) with $904M cash at year‑end, but royalty payments to Illumina (suspended until Dec 2026) will resume thereafter at a high single‑digit rate and are expected to pressure gross margins beginning in 2027.

GRAIL Stock Performance

GRAL stock opened at $50.21 on Friday. The company’s 50 day moving average price is $96.61 and its 200 day moving average price is $75.93. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -4.49 and a beta of 4.52. GRAIL has a fifty-two week low of $20.44 and a fifty-two week high of $118.84.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Company reported beats on Q4 revenue and EPS, growth in U.S. Galleri sales, stated cash runway into 2030 and completed a PMA submission to the FDA — fundamental items that support longer‑term commercialization potential. GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Topline trial data also showed a substantial reduction in stage IV diagnoses and increased stage I–II detection for some cancers — outcomes investors may view as clinically meaningful even though the primary endpoint was not met. These secondary signals could support follow‑up analyses or regulatory discussions. Landmark NHS‑Galleri Trial Demonstrates …
• Positive Sentiment: At least one research house maintained a favorable view (Outperform) after the news, indicating some analysts believe the selloff may be overdone and the company retains upside if follow‑up data or regulatory feedback is constructive. GRAIL (NASDAQ:GRAL) Earns Outperform Rating from Analysts at Robert W. Baird
• Neutral Sentiment: Several headlines and commentaries are assessing whether the market reaction is an overreaction and noting that more detailed follow‑up analyses could change interpretation — keep an eye on full data releases and management commentary. Why is GRAL stock down today? Analysts lower targets …
• Neutral Sentiment: Reported short‑interest data in the feed appears unreliable/zeroed out (likely a data error) and should not be used to infer shareholder positioning or days‑to‑cover at this time. Market data summary for GRAL
• Negative Sentiment: Primary endpoint for the 3‑year NHS‑Galleri randomized trial was not met (no statistically significant combined reduction in Stage III–IV diagnoses), which directly undercut the test’s flagship clinical claim and triggered the steep share decline. Grail shares plunge after major cancer screening trial misses main goal
• Negative Sentiment: Multiple news outlets and analysts pushed negative headlines after the trial miss, amplifying selling pressure and volatility despite the company’s otherwise positive quarterly metrics. Here’s Why Grail Stock Crashed 50% Today
• Negative Sentiment: Two law firms have opened securities‑litigation investigations into GRAIL, increasing legal risk and potential distraction for management; this typically weighs on sentiment and can prolong downside pressure. GRAL ALERT: Investigation Launched into GRAIL, Inc.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Robert W. Baird set a $82.00 target price on GRAIL in a research report on Friday. Guggenheim lifted their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Canaccord Genuity Group decreased their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, TD Cowen initiated coverage on shares of GRAIL in a research note on Thursday. They set a “hold” rating and a $114.00 price target on the stock. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $98.50.

Institutional Investors Weigh In On GRAIL

Large investors have recently modified their holdings of the company. Farallon Capital Management LLC lifted its position in shares of GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after purchasing an additional 993,684 shares during the last quarter. Morgan Stanley raised its stake in GRAIL by 63.8% in the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after buying an additional 588,647 shares in the last quarter. State Street Corp lifted its holdings in GRAIL by 38.8% during the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in GRAIL during the 4th quarter worth about $37,874,000. Finally, RA Capital Management L.P. acquired a new position in shares of GRAIL during the 4th quarter worth about $36,655,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.